Zealand Pharma A/S (Nasdaq: ZEAL) announced topline results from the multiple ascending dose (MAD) portion of a Phase 1 clinical trial for ZP9830, a Kv1.3 ion channel blocker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results